Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsies

by Florian Heil, Galina Babitzki, Alice Julien-Laferriere, Chia-Huey Ooi, Manuel Hidalgo, Christophe Massard, Maria Martinez-Garcia, Christophe Le Tourneau, Mark Kockx, Peter Gerber, Simona Rossomanno, Oliver Krieter, Angelika Lahr, Norbert Wild, Suzana Vega Harring, Katharina Lechner
Published 2021-02-01

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody

by Yvonne W. S. Jauw, Marc C. Huisman, Tapan K. Nayak, Danielle J. Vugts, Randolph Christen, Valerie Meresse Naegelen, Dominik Ruettinger, Florian Heil, Adriaan A. Lammertsma, Henk M. W. Verheul, Otto S. Hoekstra, Guus A. M. S. van Dongen, C. Willemien Menke-van der Houven van Oordt
Published 2018-01-01

370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors

by Josep Tabernero, Maurizio Ceppi, Victor Moreno, Michael Hettich, Miguel Sanmamed, Christina Claus, Tatiana Hernandez, Iben Spanggaard, Analia Azaro, Maria Martinez Garcia, Alejo Rodriguez-Vida, Florian Heil, Oliver Krieter, Oliver Grimm, Marta Canamero, Jose Duarte, Alexandra-Cristina Nica, Iakov Davydov, Chia-Huey Ooi, Christian Heichinger, Ernesto Guarin, Radoiane Helbaj, Tamara Tanos, Eveline Nueesch, Irene Moreno
Published 2020-11-01